Expertise in
2
conditions

Enzo M. Veltri

Latina, IT 
Expertise in
2
conditions
Latina, IT 

Overview

Enzo Veltri practices practicing medicine in Latina, Italy.

Mr. Veltri is highly rated in 2 conditions, according to our data. His clinical expertise encompasses HER-2 Positive Breast Cancer, Triple-Negative Breast Cancer, Breast Cancer, and Agranulocytosis.

He is actively involved in clinical research, co-authoring 33 peer reviewed articles and participating in 2 clinical trials.

Gender

Male

Locations

Latina, Italy
Other Locations
Palermo, Italy
Gaeta, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase III Study Comparing the Concurrent Versus the Sequential Administration of Chemotherapy and Aromatase Inhibitors, as Adjuvant Treatment of Post-menopausal Patients With Endocrine-responsive Early Breast Cancer.
A Phase III Study Comparing the Concurrent Versus the Sequential Administration of Chemotherapy and Aromatase Inhibitors, as Adjuvant Treatment of Post-menopausal Patients With Endocrine-responsive Early Breast Cancer.
Enrollment Status: Active_not_recruiting
Publish Date: May 06, 2026
Intervention Type: Drug
Study Drug: Anastrozole or Letrozole or Exemestane
Study Phase: Phase 3
A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
A Randomized Phase III Study Of Low-Docetaxel Oxaliplatin, Capecitabine (Low-Tox) Vs Epirubicin, Oxaliplatin And Capecitabine (Eox) In Patients With Locally Advanced Unresectable Or Metastatic Gastric Cancer
Enrollment Status: Terminated
Publish Date: October 09, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 1 Less Clinical Trial

33 Total Publications

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study.
Journal: Frontiers in oncology
Published: January 27, 2023

Frequently Asked Questions about Enzo M. Veltri

Is Enzo M. Veltri a top-rated expert for HER-2 Positive Breast Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Enzo M. Veltri is classified as an Distinguished expert for HER-2 Positive Breast Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Enzo M. Veltri participate in research or clinical trials?

Yes. Enzo M. Veltri has published 33 articles and abstracts on conditions like HER-2 Positive Breast Cancer. You can view a list of Enzo M. Veltri's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Veltri's expertise for a condition
ConditionClose
    View All 7 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile